CN113214373B - Neoechinococcosis antigen Murinoglobulin-2 protein - Google Patents

Abstract

The invention discloses a neoechinococcosis antigen Murinoglobulin-2 protein. The Murinoglobulin-2 protein provided by the invention contains all or part of the following amino acid sequences: 31-39, 89-96, 107-115, 179-200, 203-216, 225-242, 255-273, 282-300, 309-315, 336-354, 379-390 of SEQ ID No. 1. The Murinoglobulin-2 protein provided by the invention can be used for clinically detecting human echinococcosis. The invention detects 14 cases of human plasma of the postoperative echinococcosis and 6 cases of human plasma of the normal Tibetan, the positive detection rate is 86 percent, and the negative detection rate is 100 percent. The invention expands the hydatid antigen library and makes a certain contribution to the diagnosis of human echinococcosis.

Description

Neoechinococcosis antigen Murinoglobulin-2 protein

Technical Field

The invention relates to the technical field of biology, in particular to a neoechinococcosis antigen Murinoglobulin-2 protein.

Background

Echinococcosis, also known as echinococcosis, is a common disease of both humans and animals, and is especially serious in the middle and western regions of China (Tibet, Qinghai, Sichuan, Xinjiang, etc.). Human echinococcosis is mainly classified into cystic echinococcosis and alveolar echinococcosis. The imaging detection is the most intuitive and commonly used echinococcosis diagnosis method, but because the incubation period of echinococcosis is long and the echinococcosis can be detected by imaging only when the cysts formed by echinococcosis are large to a certain extent, the serological detection is one of the important auxiliary means for imaging diagnosis of echinococcosis.

To date, several methods for laboratory diagnosis of echinococcosis have been described, including the detection of antibodies, antigens and cytokines. Among them, the development of antibody detection mainly depends on the development of the kind of the hydatid antigen. However, both naturally purified and recombinantly purified antigens have certain deficiencies in specificity and/or sensitivity. More importantly, the human source hydatid etiology relates to factors such as difficulty in sampling, difficulty in separating hydatid protein and the like, and no more antigens which can be used for serological detection exist all the time. Specifically, the prior art has the following disadvantages: 1) the extraction and identification of the hydatid protein from the hydatid sac separated after the operation of the hydatid patient is a technical difficulty. If the identified hydatid proteins are of very few species, it is more difficult to select from those proteins that are likely to be antigens of hydatid. 2) The single antigen has few types. The most widely used diagnostic antigens for echinococcosis at present are Antigen B and Antigen5, and many studies show that the two antigens generate certain false positive or false negative in serum detection. 3) The commercial echinococcus antigen is a natural purified antigen, and a soluble antigen fragment isolated and purified from the crushed echinococcus granulosus is a mixture comprising a plurality of echinococcus proteins. The more proteins mixed the more likely it is to produce more false negative or false positive results in serum testing.

Disclosure of Invention

In order to overcome the defects of the prior art, the invention aims to search more antigens which can be used for diagnosing echinococcosis, expand the echinococcosis antigen database, and make the antigens, singly or in combination, possible to improve the specificity and sensitivity of laboratory diagnosis of echinococcosis. Furthermore, a mature experimental process is generated for extracting more hydatid protein from the hydatid sac separated from the patient after the operation and identifying.

In a first aspect, the present invention aims to provide a protein.

The protein provided by the invention contains all or part of the following amino acid sequences:

(1) positions 31-39 of SEQ ID No. 1;

(2) positions 89-96 of SEQ ID No. 1;

(3) position 107-115 of SEQ ID No. 1;

(4) position 179-200 of SEQ ID No. 1;

(5) position 203-216 of SEQ ID No. 1;

(6) position 225-242 of SEQ ID No. 1;

(7) position 255-273 of SEQ ID No. 1;

(8) 282-300 of SEQ ID No. 1;

(9) 309-315 of SEQ ID No. 1;

(10) 336-354 of SEQ ID No. 1;

(11) 379-390 th of SEQ ID No. 1.

Further, the protein may be any of:

(A1) protein with an amino acid sequence of SEQ ID No. 1;

(A2) protein which is obtained by substituting and/or deleting and/or adding one or more amino acid residues to the amino acid sequence shown in SEQ ID No.1 and has the same function;

(A3) a protein having 99% or more, 95% or more, 90% or more, 85% or more, or 80% or more homology with the amino acid sequence defined in any one of (A1) to (A2) and having the same function;

(A4) a fusion protein obtained by attaching a tag to the N-terminus and/or C-terminus of the protein defined in any one of (A1) to (A3).

In the above protein, the tag is a polypeptide or protein that is expressed by fusion with a target protein using in vitro recombinant DNA technology, so as to facilitate expression, detection, tracking and/or purification of the target protein. The protein tag may be a His tag, a Flag tag, an MBP tag, an HA tag, a myc tag, a GST tag, and/or a SUMO tag, among others.

In the above proteins, identity refers to the identity of amino acid sequences. The identity of the amino acid sequences can be determined using homology search sites on the Internet, such as the BLAST web pages of the NCBI home website. For example, in the advanced BLAST2.1, by using blastp as a program, setting the Expect value to 10, setting all filters to OFF, using BLOSUM62 as a Matrix, setting Gap existence cost, Per residual Gap cost, and Lambda ratio to 11, 1, and 0.85 (default values), respectively, and performing a calculation to search for identity of a pair of amino acid sequences, a value (%) of identity can be obtained.

In a specific embodiment of the present invention, the amino acid sequence of the protein is specifically identical to that of "recombinant protein obtained by inserting the DNA molecule shown in SEQ ID No.2 between the cleavage sites BamHI and XhoI of pET30a (+) plasmid and expressing the DNA molecule".

In a second aspect, the invention claims nucleic acid molecules encoding the proteins described hereinbefore.

The nucleotide sequence of the 31 st to 39 th amino acid sequences of the SEQ ID No.1 coded in the nucleic acid molecules is 91 st to 117 th of the SEQ ID No. 2;

the nucleotide sequence of the 89 th-96 th amino acid sequence of the SEQ ID No.1 in the nucleic acid molecule is the 265 th-288 th amino acid sequence of the SEQ ID No. 2;

the nucleotide sequence of the 107-115 amino acid sequence of the nucleic acid molecule is the 319-345 amino acid sequence of the nucleic acid molecule SEQ ID No. 2;

the nucleotide sequence of the 179-200 th amino acid sequence of the SEQ ID No.1 in the nucleic acid molecule is 535-600 th amino acid sequence of the SEQ ID No. 2;

the nucleotide sequence of the amino acid sequence at the 203-216 th site of the SEQ ID No.1 in the nucleic acid molecule is the 607-648 site of the SEQ ID No. 2;

the nucleotide sequence of the 225-242 th amino acid sequence of the SEQ ID No.1 in the nucleic acid molecule is 673-726 th amino acid sequence of the SEQ ID No. 2;

the nucleotide sequence of the 255-273 th amino acid sequence of the SEQ ID No.1 in the nucleic acid molecule is 763-819 of the SEQ ID No. 2;

the nucleotide sequence of the 282-position and 300-position amino acid sequence of the SEQ ID No.1 in the nucleic acid molecule is 844-900-position of the SEQ ID No. 2;

the nucleotide sequence of the 309-315 amino acid sequence of the SEQ ID No.1 in the nucleic acid molecule is 925-945 position of the SEQ ID No. 2;

the nucleotide sequence of the 336-354 amino acid sequence of the SEQ ID No.1 in the nucleic acid molecule is 1006-1062 position of the SEQ ID No. 2;

the nucleotide sequence of the 379-390 th amino acid sequence of the nucleic acid molecule SEQ ID No.1 is 1135-1170 of the nucleic acid molecule SEQ ID No. 2;

further, the nucleic acid molecule may be a DNA molecule as described in any one of:

(B1) DNA molecule shown in SEQ ID No. 2;

(B2) a DNA molecule which hybridizes under stringent conditions to the DNA molecule defined in (B1) and which encodes a protein as described hereinbefore;

(B3) a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more or 80% or more homology to the DNA sequence defined in (B1) or (B2) and encoding the protein as described above.

In the above nucleic acid molecule, the stringent conditions may be as follows: 50 ℃ in 7% Sodium Dodecyl Sulfate (SDS), 0.5M Na ₃ PO ₄ Hybridization with 1mM EDTA, rinsing in 2 XSSC, 0.1% SDS at 50 ℃; also can be: 50 ℃ in 7% SDS, 0.5M Na ₃ PO ₄ Hybridization with 1mM EDTA, rinsing at 50 ℃ in 1 XSSC, 0.1% SDS; also can be: 50 ℃ in 7% SDS, 0.5M Na ₃ PO ₄ Hybridization with 1mM EDTA, rinsing in 0.5 XSSC, 0.1% SDS at 50 ℃; also can be: 50 ℃ in 7% SDS, 0.5M Na ₃ PO ₄ Hybridization with a mixed solution of 1mM EDTA, rinsing in 0.1 XSSC, 0.1% SDS at 50 ℃; also can be: 50 ℃ in 7% SDS, 0.5M Na ₃ PO ₄ Hybridization with 1mM EDTA, rinsing in 0.1 XSSC, 0.1% SDS at 65 ℃; can also be: in a solution of 6 XSSC, 0.5% SDS at 65 ℃ and then washed once with each of 2 XSSC, 0.1% SDS and 1 XSSC, 0.1% SDS.

In a third aspect, an expression cassette or a recombinant vector or a recombinant bacterium or a recombinant cell comprising a nucleic acid molecule as described above.

Wherein the expression cassette consists of a promoter (e.g., the T7 promoter), the nucleic acid molecule, and a termination sequence (e.g., the T7 terminator). The recombinant vector may be a recombinant plasmid containing the expression cassette.

In the present invention, the promoter in the recombinant vector that initiates transcription of the nucleic acid molecule is the T7 promoter. More specifically, the recombinant vector is a recombinant plasmid obtained by inserting the nucleic acid molecule described above into the multiple cloning site (e.g., between BamHI and XhoI) of pET30a (+) plasmid.

In the present invention, the recombinant bacterium is Escherichia coli (e.g., Escherichia coli BL21(DE3)) into which the recombinant vector described above has been introduced.

In a fourth aspect, the invention claims the use of the protein or nucleic acid molecule or expression cassette or recombinant vector or recombinant bacterium or recombinant cell as described above for the preparation of a product for the diagnosis of a disease caused by echinococcus granulosus infection.

In a fifth aspect, the invention claims the use of a protein or nucleic acid molecule or expression cassette or recombinant vector or recombinant bacterium or recombinant cell as described above for the preparation of a product for the diagnosis of echinococcosis.

Wherein, the echinococcosis is preferably human echinococcosis.

In a sixth aspect, the invention claims the use of the protein or nucleic acid molecule or expression cassette or recombinant vector or recombinant bacterium or recombinant cell as described above for the preparation of a product for the detection of antibodies specific for echinococcosis.

In a seventh aspect, the present invention claims the use of the protein or nucleic acid molecule or expression cassette or recombinant vector or recombinant bacterium or recombinant cell as described above in the preparation of a product for detecting the presence of an antibody specific to echinococcosis in the serum of a subject.

In fourth to seventh aspects, the product may be a kit.

In an eighth aspect, the invention claims a kit.

The claimed kit contains the protein or nucleic acid molecule or expression cassette or recombinant vector or recombinant bacterium or recombinant cell as described above; the kit has at least one of the following functions:

(C1) diagnosing a disease caused by echinococcus granulosus infection;

(C2) diagnosing echinococcosis;

(C3) detecting an echinococcosis specific antibody;

(C4) detecting whether the serum of the person to be detected contains the echinococcosis specific antibody.

Wherein, the echinococcosis is preferably human echinococcosis.

In a particular embodiment of the invention, the kit is in particular an ELISA kit. The kit can also contain conventional reagents required by ELISA detection, such as coating solution, confining solution, washing solution, developing solution, detection secondary antibody and the like.

According to the invention, a new antigen Murinoglobulin-2 protein (SEQ ID No.1) of echinococcosis is found by gel cutting enzymolysis and mass spectrometry detection, namely a GeLS-MS/MS technology, and can be used for manufacturing an ELISA kit and clinically detecting the human echinococcosis. The echinococcosis neoantigen can be purified in large quantity, and is convenient for large-scale screening of human echinococcosis. Experiments prove that when 14 cases of postoperative echinococcosis human plasma (determined to be positive) and 6 cases of normal Tibetan human plasma (determined to be negative) are detected by using the echinococcosis neoantigen Murinoglobulin-2 protein, the positive detection rate is 86 percent, and the negative detection rate is 100 percent; the positive detection rate of the same plasma detected by the commercial antigen was 86%, and the negative detection rate was 100%. The invention expands the echinococcosis antigen library and makes a certain contribution to the diagnosis of human echinococcosis.

Drawings

FIG. 1 shows the results of SDS-PAGE and Western blotting of the total proteins extracted from seven cyst fluid fractions.

FIG. 2 shows the purification results of Murinoglobulin-2 recombinant protein. The gradient elution of Murinoglobulin-2 recombinant protein is shown in the figure, and the loading of each lane is 10. mu.l. The concentrations indicated in the figure are the concentration of imidazole in the eluent.

FIG. 3 is a WB verification experiment result of the purified Murinoglobulin-2 recombinant protein. The Murinoglobulin-2 recombinant protein group has obvious positive bands between 55KD and 43KD (the molecular weight of the Murinoglobulin-2 recombinant protein is between 55KD and 43 KD), and the commercial Antigen group has obvious positive bands between 43KD and 34KD (when commercial antigens are detected, two antigens Antigen B and Antigen5 are mainly relied on, wherein the most important molecular weight of the Antigen B which plays a function when the diagnosis of human echinococcosis is between 43KD and 34 KD). The μ g marked in the figure refers to the loading of the Murinoglobulin-2 recombinant protein.

FIG. 4 shows the result of ELISA experiment. Murinoglobulin-2_ OD (+) refers to the OD value of plasma of 14 cases of postoperative patients, and Murinoglobulin-2_ OD (-) refers to the OD value of plasma of 6 cases of normal Tibetan patients.

Detailed Description

The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.

Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

Example 1 obtaining of echinococcosis neo-antigen Murinoglobulin-2 protein

1. Process for identifying more hydatid protein by hydatid cyst separated after operation of hydatid patient

(1) Firstly, dividing the hydatid cysts separated after the operation of 6 hydatid patients into four parts to extract protein according to the tissue structure of the hydatid cysts, wherein the four parts are protocercaria, cyst fluid, a hair growth layer and a cornified cortex from inside to outside; and 6 hydatid cysts are divided into a cyst fluid transparent group and a non-transparent group according to whether cyst fluid is transparent or not.

(2) Four components of each hydatid cyst were subjected to protein extraction, and the extracted proteins were subjected to liquid enzymatic hydrolysis, followed by LC-MS/MS identification using a QE mass spectrometer.

(3) The raw data from QE was analyzed for infusor protein using maxquant protein identification software, using a pool of human and infusor protein databases (Unreviewed (TrEMBL) databases downloaded from the Uniprot (https:// www.uniprot.org /) website), and the infusor protein identification was performed, and the results were counted and the portion of the infusor containing the most infusor protein was determined, as shown in tables 1 and 2.

(4) As can be seen from table 1, there are two basic conclusions: firstly, identifying more tissue parts of echinococcus protein as cyst fluid and metacercaria; and secondly, the proteins extracted from the cyst fluid and the metacercaria of the clear cyst fluid group contain more echinococcus proteins.

(5) According to the basic conclusion I, in order to identify more echinococcus proteins, the invention additionally extracts cyst fluid and metacercaria proteins of another 10 echinococcus patients after operation, and as a result, as shown in tables 3 and 4, the cyst fluid and metacercaria part of the cyst fluid which is still a clear cyst fluid group contains more echinococcus proteins.

Protein identification results of bursa clear group in Table 16 hydatid patient groups

Note: 1 denotes miracidium; 2 denotes cyst fluid; _3denotes the stratum corneum; and 4 denotes the cornified layer.

Protein identification results of cyst fluid nontransparent group in Table 26 hydatid patient groups

Note: 1 denotes miracidium; 2 denotes cyst fluid; _3denotes the stratum corneum; and 4 denotes the cornified layer.

Protein identification results of bursa clear group in Table 310 hydatid patient groups

Note: 1 indicates metacercaria; and _2denotes cyst fluid.

TABLE 410 protein identification results of the cyst fluid nontransparent group in the hydatid patient group

Note: 1 indicates metacercaria; and 2 denotes cyst fluid.

2. Western Blotting validation, gel cutting enzymolysis and mass spectrum identification (GeLC-MS/MS)

(1) Then, according to QE identification results of cyst fluid and metacercaria of 16 samples, metacercaria and cyst fluid components of seven transparent samples with sample numbers of 1, 2, 3, 7, 8, 9 and 10 are selected to respectively carry out WB experiments with patient serum so as to verify whether immunoreactions exist between human echinococcosis and normal Tibetan human serum and the extracted holoprotein.

(2) As the total amount of protein extracted by the protozoon components of part of samples is very small and all the protein is contained in echinococcus protein identified by cyst fluid components, Western Blotting experiment of cyst fluid component protein of a clear cyst fluid sample is mainly carried out (the first antibody is a blood sample extracted before operation by a patient from which liver echinococcus is removed and is regarded as a positive blood sample of the patient suffering from echinococcosis, the second antibody is horse radish peroxidase labeled goat anti-human IgG (H + L), the manufacturer: Biyunnan day, the product number: A0201), and the result is shown in figure 1, and the immunoreaction maps of the echinococcosis person and normal Western blood serum and 7 cyst fluid clear sample cyst fluid component proteins are shown by taking the patient serum with the sample number of 1 as an example. The results prove that the cyst fluid holoprotein has strong immune response to the serum of patients, but has no response to the normal Tibetan human serum. The immunoreaction patterns of the serum of other patients and the serum of normal Tibetan patients on the protein of 7 samples are similar to those of the patient with the sample number of 1.

(3) And according to the SDS-PAGE patterns of the 7 cyst fluid components, the immunity bands of WB are contrasted to carry out gel cutting enzymolysis on SDS-PAGE gel, so that more hydatid proteins in the corresponding molecular weight sections can be identified through gel cutting separation, and the probability of finding hydatid antigens which have immunoreaction with serum is increased. In addition, this may reduce the impact of high abundance proteins on identification.

(4) In order to reduce loss and workload, the invention uniformly divides 7 cyst fluid component proteins into 10 components according to WB immune bands, and then each component is subjected to in-gel enzymolysis respectively.

(5) After LC-MS/MS analysis by QE-HF-X Mass Spectrometry, the maxquant software performed a protein pool identification using the same database as in step 1. The results are shown in Table 5.

(6) According to data analysis, the trypanosoma proteins identified by gel cutting separation of three samples 1_2, 2_2 and 10_2 comprise the trypanosoma proteins identified by the rest four samples, so that candidates of subsequent trypanosoma antigens are searched from the trypanosoma proteins identified by components of the three samples together.

TABLE 5 identification of proteins from Endocarpium capsulatum component of seven clear Endocarpium capsulatum samples by gel cutting and enzymolysis

Note: the numbers in parentheses indicate the total identified protein, while the numbers outside the parenthesis indicate the hydatid protein in each fraction. And _2denotes cyst fluid.

3. Screening of hydatid proteins as candidate antigens

(1) The common proteins identified by the same fraction in three samples served as candidate antigen pool, and finally a total of 93 unique proteins were produced by 10 fractions.

(2) These 93 proteins were first homologously aligned with the human protein database (Homo sapiens protein database by UniProt), and after deletion of the proteins with particularly high homology and those that have been selected as borrelia antigens, the remaining proteins were subjected to prediction of B-cell epitopes.

4. Epitope prediction and recombinant plasmid construction

(1) Epitope prediction uses an online prediction tool http:// tools. iedb. org/bcell/, and a sequence list about the protein which can be an epitope can be obtained by introducing the protein sequence.

(2) According to the invention, a sequence fragment containing one or more epitopes is selected to form a sequence of the recombinant protein according to an antigen epitope list of each candidate protein, the sequence is introduced into an alignment tool (https:// web. expask. org/blast /)) in an ExPasy website to be aligned with a human protein database (Homo sapiens protein database of UniProt), and only the sequence fragment with the similarity of 20% to the human protein is selected as a recombinant protein.

(3) The final 11 protein sequence fragments were inserted into pET-30a (+) plasmid by molecular cloning techniques to construct a recombinant plasmid, and the fragments were confirmed by sequencing to have been inserted.

Wherein, one recombinant protein with the amino acid sequence shown as SEQ ID No.1 is named as Murinoglobulin-2 recombinant protein. The sequence of the encoding gene of the Murinoglobulin-2 protein is shown as SEQ ID No. 2. The epitope, nucleotide sequence and amino acid sequence are shown in Table 6.

The structural description of the recombinant expression vector pET-30a-Murinoglobulin-2 for expressing Murinoglobulin-2 obtained in this step: a recombinant plasmid obtained by inserting the DNA fragment shown in SEQ ID No.2 between BamHI (GGATCC) and XhoI (CTCGAG) of pET-30a (+) plasmid. The recombinant protein expressed by the recombinant plasmid carries a 6His tag at the N-terminal.

5. Expression and purification of recombinant proteins

(1) The recombinant plasmid is transferred into escherichia coli BL21(DE3) for small-scale test expression, and after the fact that the protein can be expressed and the molecular weight is correct is confirmed, amplification culture is carried out.

(2) After the collected bacterial liquid is subjected to ultrasonic protein extraction, nickel column purification is carried out through His-tag carried by plasmid, figure 2 shows the purification result of the Murinoglobulin-2 recombinant protein, and the arrow indicates the target protein. In the following experiments (such as Western Blotting experiment and ELISA experiment), target protein eluted at an imidazole concentration of 250mM is estimated to have a purity of about 95%.

6. Western Blotting validation of Murinoglobulin-2 recombinant protein

(1) The purified 11 recombinant proteins are respectively subjected to Western Blotting experiments with 16 sera of patients suffering from the postoperative echinococcosis (the primary antibody is a blood sample extracted from a patient without the liver echinococcosis before surgery and is considered to be a blood sample determined to be positive by the echinococcosis; the secondary antibody is horseradish peroxidase-labeled goat anti-human IgG (H + L), the manufacturer is Biyunshi, the product number is A0201, meanwhile, the purchased commercial antigen (echinococcosis/echinococcus granulosus antigen is an imported natural purified antigen, a soluble fragment separated and purified from the broken echinococcus granulosus is widely applied to colloidal gold, ELISA and the like; the manufacturer is Hangzhou minobio-technology limited, the product number is YM-VI08) is also subjected to WB experiments with the 16 sera, and the result shows that only 4 recombinant proteins have immunoreaction with the sera of the patients to be more than or equal to the commercial antigen, therefore, the 4 recombinant proteins are selected as the candidate of the hydatid antigen to carry out ELISA verification tests on the serums of more patients. One of the Murinoglobulin-2 recombinant proteins is Murinoglobulin-2.

(2) FIG. 3 shows the WB experiment results of Murinoglobulin-2 recombinant protein and commercial antigen with 16 patient sera. The results show that: the immunoreactivity of the Murinoglobulin-2 recombinant protein is 94 percent, and the immunoreactivity of the commercial antigen is 75 percent.

TABLE 6B-cell epitopes, nucleotide and amino acid sequences of Murinoglobulin-2 recombinant proteins

Example 2 case for verifying ELISA experiment of recombinant protein Murinoglobulin-2, recombinant antigen of hydatid

The tested objects are 14 cases of postoperative echinococcosis human plasma (clinically determined to be positive) and 6 cases of normal Tibetan human plasma (clinically determined to be negative), the operation is carried out according to the standard operation steps of indirect ELISA, and the result shows that the positive detection rate of Murinoglobulin-2 recombinant protein (obtained by purifying the protein obtained in the example 1, namely the target protein eluted when the imidazole concentration is 250mM in the figure 2) is 86 percent, and the negative detection rate is 100 percent; and the positive detection rate and the negative detection rate of the same blood plasma are 86% and 100% when the same blood plasma is detected by using a commercial antigen (echinococcosis/echinococcus granulosus antigen, manufacturer: Yiminou Biotechnology Co., Ltd., Hangzhou, product number: YM-VI 08).

1. Specific operation steps of ELISA experiment

(1) Antigen quantification: each antigen was blown evenly using a pipette gun before coating and quantitated using a micro uv spectrophotometer to ensure that the protein was not degraded. No absorption peak at A280 indicates that the antigen amount is very low and is not suitable for coating; if the protein is separated out or insoluble, 8M urea is dripped into the mixture and then the mixture is evenly blown, centrifuged and the supernatant is taken for measuring the concentration.

(2) Coating: comparing the concentration of the antigen tube wall with the measured value, and obtaining a low value (the concentration of the protein measured after purification can be marked on the wall of the centrifugal tube, the concentration needs to be measured again after the protein is stored at-20 ℃ for a period of time, and the ELISA experiment is carried out on the two low values); coating amount is 2 mug/ml and 10 ml/plate, and coating antigen amount is prepared according to actual use amount; labeling on coated ELISA plate: antigen number, name, label, coating date, plate number and the like, and if the coating concentration is not 2 mug/ml, the coating concentration needs to be indicated (the actual coating amount of the Murinoglobulin-2 recombinant protein and the commercial antigen in the experiment is specifically 200 ng/well). After labeling the ELISA plates, coating antigen was added at 100. mu.l/well, coated overnight at 4 ℃ or coated for 2h at 37 ℃. Wherein the coating solution is sodium carbonate-sodium bicarbonate buffer solution, and the pH value is 9.6: na (Na) ₂ CO ₃ 1.59g；NaHCO ₃ 2.93g, pure water to 1000 ml; and finally, detecting the pH value by using pH test paper, and storing at 4 ℃.

(3) Washing the plate: the coated board is washed for 1 time by a board washing machine and then is patted dry on absorbent paper. The formula of the 50X lotion is as follows: 154.4g of Tris; 149.0g of NaCl; 24.0ml of Tween-20; 800ml of pure water; the pH of the solution was adjusted to 7.2 with about 45ml of concentrated hydrochloric acid, and the volume of pure water was adjusted to 1000 ml. Storing at 4 deg.C.

(4) And (3) sealing: 2% skimmed milk powder as sealing liquid, sealing at 200 μ l/well at 4 deg.C overnight or at 37 deg.C for 2 hr.

(5) Washing the plate: the closed plate is washed 1 time with a plate washer and then patted dry on absorbent paper.

(6) Plus primary (echinococcosis human plasma or normal Tibetan human plasma without echinococcosis): the corresponding primary antibody was added using PBS in a ratio of 1: the plasma was diluted 500 (vol.) and incubated at 37 ℃ for 1 h.

(7) Washing the plate: washing the plate for more than 3 times by a plate washing machine, and patting the plate on absorbent paper.

(8) Adding a secondary antibody: since the primary antibody was derived from human plasma, the secondary antibody (horseradish peroxidase-labeled goat anti-human IgG (H + L), manufactured by Biyuntian; cat # A0201) used goat anti-human 1: 500 (by volume) was added and incubated at 37 ℃ for 1 h.

(9) Washing the plate: washing the plate for more than 3 times by a plate washing machine, and patting the plate on absorbent paper. And preparing a color development liquid (TMB) while washing the plate.

(10) Color development: after the stop solution is prepared, 100 mul/hole of the color developing solution is added, and the plate can be shaken to accelerate the color developing process and pay attention to close observation.

(11) TMB color development: when the color development reaches a certain degree (the blank and negative color development can not be too high generally), adding 50 mu l/hole stop solution, standing for more than 10min after adding the stop solution to ensure complete termination and uniform color (the plate can be shaken to accelerate the termination process), and reading after termination.

(12) Reading: preheating a microplate reader for more than 30 min; the TMB color development detection wavelength is as follows: 450 nm. And opening corresponding microplate reader measurement software, and reading. Store the data to the specified location and refine the data.

(13) Note that: when the 96-well plate is loaded with a gun, care is taken to avoid the formation of bubbles and to avoid wall-hanging of the loaded sample. After the sample is added, observing the whole plate, and requiring no bubbles at the bottom of the hole; when bubbles are found, the plate is shaken or the head of the gun is used for removing the bubbles. When the plate is washed, close attention is needed to ensure complete and thorough plate washing. The color development needs to be closely paid attention, and the color development of negative, blank and positive controls is timely stopped.

2. ELISA results and analysis

(1) The results of detecting OD values of 14 cases of post-operative echinococcosis human plasma (determined to be positive) and 6 cases of normal Tibetan human plasma (determined to be negative) by echinococcosis antigen immunization are shown in FIG. 4.

(2) And (3) negative and positive judgment standard: and selecting the average value (X) and Standard Deviation (SD) of the negative serum samples, wherein the upper limit cut-off value of the confidence interval is X +3 SD. The OD value of the sample to be detected at 450nm is more than or equal to X +3SD, and the sample to be detected at less than X +3SD can be judged as positive, and the sample to be detected at 450nm can be judged as negative.

(3) Through calculation, 14 cases of postoperative echinococcosis human plasma (determined to be positive) and 6 cases of normal Tibetan human plasma (determined to be negative) are immunized by using the echinococcus antigen Murinoglobulin-2 recombinant protein, the positive detection rate is 86 percent and the negative detection rate is 100 percent respectively; the positive detection rate of the same plasma detected by the commercial antigen was 86%, and the negative detection rate was 100%. Therefore, the new recombinant protein Murinoglobulin-2 serving as the hydatid antigen reaches the level of the existing commercial antigen in both positive detection rate and negative detection rate. The invention expands the echinococcosis antigen library and makes a certain contribution to the diagnosis of human echinococcosis.

<110> Shenzhen Hua Dagen shares GmbH

<120> neoechinococcosis antigen Murinoglobulin-2 protein

<130> GNCLN200349

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 390

<212> PRT

<213> Artificial sequence

<400> 1

Met Arg Ala Leu Ala Cys Ala Leu Thr Ala Leu Leu Cys Phe Val Thr

1 5 10 15

Thr Ala Phe Ile Val Gly Pro Arg Arg Leu Pro Arg Phe Leu Asp Ala

20 25 30

Asn Asn Thr Val Thr Ile Ser Leu Pro Gln Glu Leu Phe Val Asp Leu

35 40 45

Pro Asn Thr Phe Ile Val Arg Ser Leu Lys Pro Leu Ser Asn Val Val

50 55 60

Val Tyr Met Thr Thr Tyr Gly Leu Asn Thr Gln Asn Val Gly Leu Val

65 70 75 80

Asn Phe Asp Gln Leu His Val Asn Lys Cys Arg Asp Asp Asp Met Tyr

85 90 95

Thr Tyr His Leu Lys Tyr Phe Val Pro Ile Glu Leu Lys Pro Gly Thr

100 105 110

Arg Ile Asn Leu Asn Val Thr Tyr Leu Tyr Cys Pro Ser Asn Thr Cys

115 120 125

Lys Asp Ala Asp Glu Val Thr Ala Gly Asn Val Asp Arg Ser Val Gln

130 135 140

Ile Val Ser Arg Phe Ala Val Ile Met Gly Glu Thr Asp Lys Pro Leu

145 150 155 160

Tyr Arg Pro Gly Asp Gln Val Arg Leu Arg Phe Leu Ala Leu Thr Ser

165 170 175

Arg Thr Ile Leu Pro Gln Thr Glu Pro Leu Thr Trp Pro Arg Tyr Arg

180 185 190

Ala Val Gly Glu Tyr Trp Glu Glu Lys Arg Leu Glu Ile Ile Glu Pro

195 200 205

Ser Glu Arg Glu Arg Arg Met Lys Ala Pro Phe Phe Asp Cys Ile Glu

210 215 220

Ile Lys Asp Pro Leu Asp Asn Ile Val Gln Gln Trp Lys Asp Val Lys

225 230 235 240

Pro Leu Glu Ala Leu Asn Leu Thr Tyr His Leu Ile Ser Asp Ala Met

245 250 255

Glu Gly Glu Trp Lys Ile Glu Ala Arg Val Lys Asp Glu Ser Glu Glu

260 265 270

Ile Arg Phe Gln Val Arg His Tyr Val Gln Pro Arg Phe Gln Ala His

275 280 285

Val Glu Met Pro Lys Ala Ile Gln Pro Ala Asp Ala Glu Ile Ile Phe

290 295 300

Lys Val Cys Ala Ala Tyr Thr Asn Gly His Ala Met Met Gly Ala Phe

305 310 315 320

Asp Ala Gln Ile Cys Val Cys Asn Gln Asn Val Leu Glu Leu His Gln

325 330 335

Thr Ser Lys Gln Leu Ile Pro Lys Asn Gln Cys Pro Gly Tyr His Asn

340 345 350

Ser Ile Thr Arg Thr Cys Met Arg Phe Asn Gly Val Ile Asp Ser Leu

355 360 365

Ala Cys Ser Thr Ile Thr Ala Asn Ile Ser Gln Leu Val Gly Ser Gln

370 375 380

Pro Pro Ser Trp Met Asp

385 390

<210> 2

<211> 1170

<212> DNA

<213> Artificial sequence

<400> 2

atgcgtgcat tggcgtgcgc actaacagcg cttttgtgct ttgtcacaac agctttcatc 60

gtaggtccac gaagactccc tcgcttcctt gatgccaata acactgtcac catctccttg 120

cctcaggaac tgtttgtcga tctccctaac acatttattg ttcgctcact caaacccctc 180

tccaacgttg tggtttacat gacaacttat gggctcaaca cgcagaatgt cggtctggtg 240

aatttcgacc aattgcatgt gaacaaatgc agagatgacg acatgtacac ctaccacttg 300

aagtactttg tgccgattga gctgaaacct ggcacccgaa tcaatctcaa tgtcacctac 360

ctctactgcc cgtctaatac ctgcaaggat gcagacgaag tgacagctgg gaatgttgac 420

aggtctgttc aaatagtgag ccgatttgct gtgattatgg gggagactga taagccactc 480

taccgacctg gtgatcaggt gagattgcgc ttccttgcac ttactagtcg taccatcttg 540

ccgcaaactg aaccgcttac atggccaaga tatcgtgctg ttggtgagta ctgggaagag 600

aagaggctcg aaatcataga gccaagtgaa cgcgagagac ggatgaaagc accgttcttt 660

gattgcattg aaataaagga cccacttgac aatattgtac agcagtggaa ggatgtcaaa 720

ccattggaag ctctcaatct gacctaccat ctcattagtg acgccatgga aggtgaatgg 780

aaaatagagg cccgtgtgaa ggatgaaagt gaggagataa gattccaagt gaggcactac 840

gttcaaccgc ggttccaggc acacgtagag atgccgaagg ccattcagcc agcagatgcg 900

gagataatat tcaaggtgtg tgctgcttac accaatggtc atgccatgat gggcgcattt 960

gatgctcaaa tctgcgtctg taatcagaat gtattggagc tccaccaaac gtcaaagcag 1020

ctcataccga agaaccaatg ccctggttac cacaattcaa tcacgcgcac gtgtatgcgc 1080

ttcaacggtg tcatagacag cctcgcttgc agtactatta cagccaatat ctcacaactg 1140

gttgggagcc aaccaccaag ctggatggac 1170

Claims (9)

1. A protein, which is any one of:

(A1) the amino acid sequence is shown as SEQ ID No. 1;

(A2) and (B) attaching a label to the N-terminus and/or C-terminus of the protein defined in (A1).

2. A nucleic acid molecule encoding the protein of claim 1.

3. The nucleic acid molecule of claim 2, wherein: the nucleic acid molecule is a DNA molecule shown in SEQ ID No. 2.

4. An expression cassette or recombinant vector or recombinant bacterium or recombinant cell comprising the nucleic acid molecule of claim 2 or 3.

5. Use of the protein according to claim 1 or the nucleic acid molecule according to claim 2 or 3 or the expression cassette or recombinant vector or recombinant bacterium or recombinant cell according to claim 4 for the preparation of a product for the diagnosis of a disease caused by echinococcus granulosus infection.

6. Use of the protein according to claim 1 or the nucleic acid molecule according to claim 2 or 3 or the expression cassette or recombinant vector or recombinant bacterium or recombinant cell according to claim 4 for the preparation of a product for the diagnosis of echinococcosis.

7. Use of the protein of claim 1 or the nucleic acid molecule of claim 2 or 3 or the expression cassette or recombinant vector or recombinant bacterium or recombinant cell of claim 4 for the preparation of a product for the detection of antibodies specific for echinococcosis.

8. Use of the protein of claim 1 or the nucleic acid molecule of claim 2 or 3 or the expression cassette or recombinant vector or recombinant bacterium or recombinant cell of claim 4 for the preparation of a product for detecting the presence of an antibody specific for echinococcosis in the serum of a subject.

9. A kit comprising the protein of claim 1 or the nucleic acid molecule of claim 2 or 3 or the expression cassette or recombinant vector or recombinant bacterium or recombinant cell of claim 4; the kit has at least one of the following functions:

(C1) diagnosing a disease caused by echinococcus granulosus infection;

(C2) diagnosing echinococcosis;

(C3) detecting an echinococcosis specific antibody;

(C4) detecting whether the serum of the person to be detected contains the echinococcosis specific antibody.

Images